Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ImmPRes - PBMC derived CD4 and CD8 T cells

ABSTRACT: Dataset release from the Immunological Proteome Resource (ImmPRes). This dataset contains proteomic data from human CD4 and CD8 T cells isolated from PBMC. T-cells were activated with OKT3 antibody (anti CD3) and IL-2 for three days, then expanded in IL-2 until day 7. Cells were then sorted into live CD4 and CD8 T-cells.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Primary Cell, T Cell, Cell Culture

SUBMITTER: Christina Rollings

LAB HEAD: Doreen Cantrell

PROVIDER: PXD063325 | Pride | 2025-04-25

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SP1_1.raw	Raw
	SP1_10.raw	Raw
	SP1_11.raw	Raw
	SP1_12.raw	Raw
	SP1_13.raw	Raw

Items per page:

1 - 5 of 99

Similar Datasets

E-GEOD-50121

Project description:Runx3 function in IL-2-activated splenic CD8+ T cells

2015-07-13 | E-GEOD-50121 | ExpressionAtlas

E-MTAB-5338

Project description:RNAseq analysis of CD4 and CD8 T cells in response to vaccinia virus infection

2019-05-14 | E-MTAB-5338 | ExpressionAtlas

E-GEOD-6740

Project description:Transcription profiling by array of human CD4+ and CD8+ T cells from HUV patients

2025-01-24 | E-GEOD-6740 | ExpressionAtlas

E-MTAB-2960

Project description:CD3/CD28 and IL-2 stimulated mouse CD8 T cells with or without anti-CD132 blocking antibody

2014-09-24 | E-MTAB-2960 | ExpressionAtlas

E-GEOD-14926

Project description:Transcription profiling by array of human CD4 positive and CD8 positive T cells selected by positive or negative immunomagnetic cell selection

2025-01-24 | E-GEOD-14926 | ExpressionAtlas

E-GEOD-41090

Project description:Mouse CD4+/CD8+ thymocytes from miR-181a1/b1 KO vs WT

2019-05-14 | E-GEOD-41090 | ExpressionAtlas

E-GEOD-50122

Project description:Runx3 function in splenic NK cells (IL-2 or IL-15)

2015-07-13 | E-GEOD-50122 | ExpressionAtlas

E-GEOD-50119

Project description:Runx3 function in CD8+ splenic T cells

2015-07-13 | E-GEOD-50119 | ExpressionAtlas

Adenovirus Serotype 5 Vectors Trigger IL-27-Dependent Inhibitory CD4+ T Cell Responses

Project description:Viral vectors are attractive vaccine platforms that elicit robust innate and adaptive immune responses; however, viral vector vaccine candidates vary greatly in their ability to induce protective immunity. Ad5 vectors elicit robust CD8+ T cell responses but typically characterized by an exhausted phenotype. The mechanisms by which Ad5 vectors induce dysfunctional CD8+ T cells have not been fully elucidated. Here we demonstrate that Ad5 vectors, but not Ad26 vectors, elicit exhausted antigen-specific IL-10+PD1+ CD4+ T cells with a dysfunctional transcriptional profile, and these cells effectively suppress CD8+ T cells responses in vivo. Induction of inhibitory CD4+ T cells by Ad5 vectors was associated with increased IL-27 expression, and IL-27 blockade improved CD4+ T cell polyfunctionality. Together our data highlight a novel role for IL-27 in regulating responses to viral vector vaccines. Splenic CD45.2+ OT-II TCR-Tg CD4 T cells from CD45.1+ B6 mice immunized with Ad5-OVA or Ad26-OVA were purified by FACS on day 10 post-immunization

2016-06-01 | E-GEOD-73118 | biostudies-arrayexpress

Phosphoproteomic analysis of IL-2 MSA and IL-12 MSA combination on T cell signaling

Project description:Engineered cytokine-based approaches for immunotherapy of cancer are poised to enter the clinic, with IL-12 being at the forefront. However, little is known about potential mechanisms of resistance to cytokine therapies. We found that orthotopic murine lung tumors were resistant to systemically delivered IL-12 fused to murine serum albumin (MSA, IL12-MSA) due to low IL-12R expression on tumor-reactive CD8+ T cells. IL2-MSA increased binding of IL12-MSA by tumor-reactive CD8+ T cells, and combined administration of IL12-MSA and IL2-MSA led to enhanced tumor-reactive CD8+ T cell effector differentiation, decreased numbers of tumor-infiltrating CD4+ regulatory T (Treg) cells, and increased survival of lung tumor-bearing mice. Predictably, the combination of IL-2 and IL-12 at therapeutic doses led to significant dose-limiting toxicity. Administering IL-12 and IL-2 analogs with preferential binding to cells expressing IL12rb1 and CD25, respectively, led to a significant extension of survival in mice with lung tumors while abrogating dose-limiting toxicity. These findings suggest that IL-12 and IL-2 represent a rational approach to combination cytokine therapy whose dose-limiting toxicity can be overcome with engineered cytokine variants.

2024-01-26 | PXD044740 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data